Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 8)
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Weight Loss Meds Help Stroke Survivors Prevent Stroke Recurrence, Death
MONDAY, Nov. 11, 2024 – The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart attack or death, a new study says. GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes m...
Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
THURSDAY, Nov. 7, 2024 – The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have...
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
THURSDAY, Nov. 7, 2024 – Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could...
Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period
TUESDAY, Nov. 5, 2024 – In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, recommendations are presented for the safe use of...
Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
TUESDAY, Nov. 5, 2024 – Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow Medicaid to cover t...
ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer
FRIDAY, Nov. 1, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of...
Semaglutide Linked to Reduced Risk for Alzheimer Diagnosis in T2DM
FRIDAY, Nov. 1, 2024 – For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic...
Ozempic, Wegovy Could Help Ease Knee Arthritis Pain
FRIDAY, Nov. 1, 2024 – The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found. People who received weekly injections of semaglutide – the active...
Semaglutide Beneficial for People With Obesity, Knee Osteoarthritis
THURSDAY, Oct. 31, 2024 – For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and pain related to knee osteoarthritis than placebo,...
Most Patients Can Keep Using GLP-1 Weight Loss Meds Before Surgeries
THURSDAY, Oct. 31, 2024 – A new guidance issued jointly by groups representing U.S. surgeons, anesthesiologists and gastroenterologists affirms that most people taking popular GLP-1 weight-loss meds...
Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
TUESDAY, Oct. 29, 2024 – Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as antiobesity treatment from 2022 to 2023, with a...
Ozempic Curbs Kidney Disease in Obese People Without Diabetes
MONDAY, Oct. 28, 2024 – The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows. Patients taking semaglutide – the active agent in Ozempic and Wegovy – had...
Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds
FRIDAY, Oct. 25, 2024 – As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds....
Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
THURSDAY, Oct. 24, 2024 – Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says. People with type 2 diabetes taking s...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2